Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)
Lexeo Therapeutics recorded quarterly Preferred Stock Liabilities of $99.8 million in Q3 2023, down 46.08% quarter-over-quarter from $185.0 million in Q2 2023, and down 46.08% year-over-year from $185.0 million in Q3 2022.
Lexeo Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $99.8 million for Q3 2023.
- In Q3 2023, Preferred Stock Liabilities fell 46.08% year-over-year to $99.8 million; the TTM figure through Sep 2023 stood at $99.8 million (down 46.08% YoY), while the FY2022 annual figure was $185.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $99.8 million for Q3 2023 at Lexeo Therapeutics, down from $185.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $185.0 million in Q3 2022 to a low of $99.8 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 99.77 Mn |
| Jun 30, 2023 | 185.03 Mn |
| Mar 31, 2023 | 185.03 Mn |
| Dec 31, 2022 | 185.03 Mn |
| Sep 30, 2022 | 185.03 Mn |